FIDO*98* said:
gkaggie08 said:
FIDO*98* said:
Oral Semaglutide doesn't have near the same weight loss results and significantly more side effects. They're giving is away because they can't sell it. More window dressing
I have no reason to not believe you. But I also have no reason to believe you. I'm not a doctor or biomedical scientist. Care to post some evidence for your claim?
I've spent my entire career in Endocrinology in Pharma and now Device. Rybelsus shows 6% body weight reduction over 12mo vs 15% with Ozympic. 98mg weekly vs 2% for Ozympic. The poor absorption orally leads to the additional GI side effects. Doctors don't use oral Semaglutide unless there are circumstances such as sever needle phobia. Patients are also far less compliant with daily vs weekly medication schedules
Just a quick search but it appears that the oral formulation has very similar weight loss and side effects to injectible.
AI CLIP:
As of my last update in early 2023, Wegovy (semaglutide) was approved as a once-weekly injectable, not a pill. However, a daily oral pill formulation
of semaglutide for weight management was in advanced clinical development and has since been approved in some regions, though it's important to
differentiate it from the injectable Wegovy.
Assuming you're asking about the oral semaglutide specifically for weight management (marketed as
Rybelsus for diabetes, but used off-label or in higher doses for weight management under another name in future approvals):
Here's a summary of the
medical data for oral semaglutide for weight management, primarily based on the OASIS 1 trial (a key Phase 3 trial for the oral formulation):
Key
Findings & Efficacy:
Significant Weight Loss: Oral semaglutide at a 50 mg daily dose demonstrated substantial and clinically meaningful weight loss compared to placebo. In the OASIS 1 trial:Participants receiving oral semaglutide 50 mg experienced an average weight loss of approximately 15.1%(around 15 kg or 33 lbs) over 68 weeks.
This was significantly greater than the placebo group, which had a minimal weight loss of around 2.4%.
High
Proportion of Responders: A large percentage of individuals achieved significant weight loss:
Around 85% of participants on oral semaglutide 50 mg
achieved at least 5% body weight reduction.
Approximately 69% achieved at least 10% body weight reduction.
Around 50% achieved at least 15% body
weight reduction.
Improved Cardiometabolic Markers: Similar to the injectable formulation, oral semaglutide also showed improvements in various
cardiometabolic parameters, including:
Reduction in waist circumference.
Improvements in blood pressure.
Lowering of HbA1c (in individuals with
prediabetes or type 2 diabetes).
Improvements in lipid profiles.
Mechanism of Action: Oral semaglutide, like its injectable counterpart, is a GLP-1
receptor agonist. It works by:
Mimicking the GLP-1 hormone, which regulates appetite and food intake.
Increasing feelings of fullness and
satiety.
Reducing hunger and cravings.
Slowing gastric emptying.
Safety and Side Effects:
Gastrointestinal (GI) Side Effects are Common: The most
frequently reported side effects are GI-related, consistent with other GLP-1 RAs:
Nausea, vomiting, diarrhea, and constipation are the most
common.
These are generally mild to moderate in severity and tend to decrease over time as the body adjusts to the medication (especially with gradual
dose escalation).
Serious Adverse Events: Less common but potential serious adverse events include:
Pancreatitis: A rare but serious risk,
consistent with other GLP-1 RAs.
Gallbladder-related issues: Including cholelithiasis (gallstones).
Thyroid C-cell tumors: A black box warning
regarding a potential risk of thyroid C-cell tumors (specifically medullary thyroid carcinoma or MTC) based on rodent studies. It's contraindicated in
patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance to humans is
still being studied.
Hypoglycemia: Risk of hypoglycemia is low in non-diabetic individuals but can occur if used with other glucose-lowering
medications (e.g., insulin or sulfonylureas in diabetic patients).
Kidney Injury: Acute kidney injury and worsening of chronic renal failure have been
reported, sometimes requiring hemodialysis, in patients treated with GLP-1 RAs; a causal relationship has not been established.
Administration and
Dosing:
Oral semaglutide for weight management is taken once daily.
It requires specific administration instructions: taken on an empty stomach with
a small amount of water (no more than 4 ounces), at least 30 minutes before the first food, drink, or other oral medications of the day. This is
crucial for its absorption.
The dose is gradually titrated upwards over several weeks to minimize GI side effects, reaching the target dose of 50 mg
daily.
Comparisons to Injectable Wegovy:
The 50 mg oral semaglutide dose achieved comparable weight loss to the 2.4 mg injectable Wegovy in clinical
trials (around 15% body weight reduction). This suggests it offers a similar level of efficacy.
The primary differentiator is the route of
administration (oral pill vs. subcutaneous injection), offering a preference for patients who dislike injections.
The safety profile and side effects
are largely similar, with GI issues being predominant for both.Important Considerations:
Oral semaglutide for weight management is intended for
long-term use, typically alongside a reduced-calorie diet and increased physical activity.
It's generally prescribed for individuals with obesity (BMI
30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia).
In
summary, the medical data for oral semaglutide for weight management shows it to be a highly effective medication for significant weight loss, with a
safety profile consistent with other GLP-1 receptor agonists, primarily characterized by common but usually manageable gastrointestinal side
effects.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with a
healthcare provider for diagnosis and treatment. The specific brand name and availability for the oral semaglutide 50mg for weight management may vary
by region and approval status.
No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. See full
Medical Disclaimer.